{"schema_version":"1.0","type":"article","title":"「一針近 50 萬美元」有證據嗎？Moderna 三期後真正要算的四筆帳","url":"https://drugnews.com.tw/articles/2026-09-09-personalized-mrna-cancer-vaccine-economics.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-09-personalized-mrna-cancer-vaccine-economics.md","lang":"zh-Hant","date":"2026-09-09","publish_at":"2026-09-09T08:00:00+08:00","updated_at":"2026-09-09","category":"商業分析系列","topic":"商業分析系列","tags":["個人化癌症疫苗","mRNA","intismeran","臨床開發","生技商業化"],"summary":"個人化 mRNA 癌症疫苗三期頂線陽性，不等於已核准或已有正式藥價。intismeran 的商業化，還要算清患者批次、交付時間、支付價值與平行產能。","key_points":[],"facts":[],"sections":["🧬 01｜第一筆帳：每位病人都要有自己的批次","⏱️ 02｜第二筆帳：病人等不等得起","💳 03｜第三筆帳：支付方到底在買什麼","🏭 04｜第四筆帳：規模化不是「多做一樣的藥」","🔬 05｜III 期達標，不等於所有答案都揭曉","🧾 06｜「一針」三個字，把價格問題說得太簡單","📦 07｜名目產能之外，還有六個關鍵轉換率","🧭 08｜一款藥與一個平台，估值不能混在一起","🧬 09｜這不是「把腫瘤磨成疫苗」，而是把突變翻成免疫名單","🏥 10｜醫院端不是收貨而已，而是整條個人化供應鏈的起點","⚖️ 11｜多頭與空頭情境，分別要看到什麼","🇹🇼 12｜台灣的機會，不是先喊「受益股」","🎯 結語｜三期成功證明前半句，商業化要證明後半句"],"references":[],"images":[{"alt":"一人一批的個人化癌症疫苗製造概念，並列製造、時間、支付及規模四項成本。","url":"https://drugnews.com.tw/assets/articles/personalized-mrna-cancer-vaccine-economics/01_economics_zh_r2.png"},{"alt":"腫瘤與血液取樣、定序、新抗原選擇、mRNA 製造、品質檢驗與肌肉注射的六步概念流程。","url":"https://drugnews.com.tw/assets/articles/personalized-mrna-cancer-vaccine-economics/02_patient_batch_zh_r1.png"},{"alt":"INTerpath-001 以二比一隨機分組，intismeran 加 KEYTRUDA 與安慰劑加 KEYTRUDA 共同比較 RFS 及 DMFS。","url":"https://drugnews.com.tw/assets/articles/personalized-mrna-cancer-vaccine-economics/03_trial_endpoints_zh_r2.png"},{"alt":"新抗原預測、患者批次平行製造、放行或暫停的品質判斷，以及物流與醫院身分核對四套系統。","url":"https://drugnews.com.tw/assets/articles/personalized-mrna-cancer-vaccine-economics/04_scaleout_zh_r2.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/personalized-mrna-cancer-vaccine-economics/00_cover_no_text_r1.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-09）。「一針近 50 萬美元」有證據嗎？Moderna 三期後真正要算的四筆帳。https://drugnews.com.tw/articles/2026-09-09-personalized-mrna-cancer-vaccine-economics.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}